Literature DB >> 27596696

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.

Grant E Barber1, Vijay Yajnik1, Hamed Khalili1, Cosmas Giallourakis1, John Garber1, Ramnik Xavier1, Ashwin N Ananthakrishnan1.   

Abstract

OBJECTIVES: One-fifth of patients with Crohn's disease (CD) are primary non-responders to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10-15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify genetic factors associated with primary non-response (PNR) and loss of response to anti-TNFs in CD.
METHODS: From a prospective registry, we characterized the response of 427 CD patients to their first anti-TNF therapy. Patients were designated as achieving primary response, durable response, and non-durable response based on clinical, endoscopic, and radiologic criteria. Genotyping was performed on the Illumina Immunochip. Separate genetic scores based on presence of predictive genetic alleles were calculated for PNR and durable response and performance of clinical and genetics models were compared.
RESULTS: From 359 patients, 36 were adjudged to have PNR (10%), 200 had durable response, and 74 had non-durable response. PNRs had longer disease duration and were more likely to be smokers. Fifteen risk alleles were associated with PNR. Patients with PNR had a significantly higher genetic risk score (GRS) (P =8 × 10-12). A combined clinical-genetic model more accurately predicted PNR when compared with a clinical only model (0.93 vs. 0.70, P <0.001). Sixteen distinct single nucleotide polymorphisms predicted durable response with a higher GRS (P =7 × 10-13). The GRSs for PNR and durable response were not mutually correlated, suggesting distinct mechanisms.
CONCLUSIONS: Genetic risk alleles can predict primary non-response and durable response to anti-TNF therapy in CD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27596696      PMCID: PMC5143156          DOI: 10.1038/ajg.2016.408

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

Authors:  Matthieu Allez; Konstantinos Karmiris; Edouard Louis; Gert Van Assche; Shomron Ben-Horin; Amir Klein; Janneke Van der Woude; Filip Baert; Rami Eliakim; Konstantinos Katsanos; Jørn Brynskov; Flavio Steinwurz; Silvio Danese; Severine Vermeire; Jean-Luc Teillaud; Marc Lémann; Yehuda Chowers
Journal:  J Crohns Colitis       Date:  2010-06-29       Impact factor: 9.071

2.  Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.

Authors:  Matthias Jürgens; Rüdiger P Laubender; Franziska Hartl; Maria Weidinger; Julia Seiderer; Johanna Wagner; Martin Wetzke; Florian Beigel; Simone Pfennig; Johannes Stallhofer; Fabian Schnitzler; Cornelia Tillack; Peter Lohse; Burkhard Göke; Jürgen Glas; Thomas Ochsenkühn; Stephan Brand
Journal:  Am J Gastroenterol       Date:  2010-03-02       Impact factor: 10.864

3.  Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.

Authors:  Gary Toedter; Katherine Li; Colleen Marano; Keying Ma; Sarah Sague; C Chris Huang; Xiao-Yu Song; Paul Rutgeerts; Frédéric Baribaud
Journal:  Am J Gastroenterol       Date:  2011-03-29       Impact factor: 10.864

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

6.  Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study.

Authors:  Vinciane Dideberg; Edouard Louis; Frédéric Farnir; Sabrina Bertoli; Séverine Vermeire; Paul Rutgeerts; Martine De Vos; André Van Gossum; Jacques Belaiche; Vincent Bours
Journal:  Pharmacogenet Genomics       Date:  2006-05       Impact factor: 2.089

7.  IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

Authors:  Elena Urcelay; Juan-Luis Mendoza; Alfonso Martinez; Laura Fernandez; Carlos Taxonera; Manuel Diaz-Rubio; Emilio-G de la Concha
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

8.  Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.

Authors:  V Pittoni; M Bombardieri; F R Spinelli; R Scrivo; C Alessandri; F Conti; A Spadaro; G Valesini
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

9.  NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Authors:  Jan Hendrik Niess; Jochen Klaus; Johannes Stephani; Carolin Pflüger; Nadine Degenkolb; Ulrike Spaniol; Benjamin Mayer; Georgia Lahr; Georg B T von Boyen
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

10.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  27 in total

1.  Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease.

Authors:  Hideki Iijima; Taku Kobayashi; Mitsuo Nagasaka; Shinichiro Shinzaki; Kazuya Kitamura; Yasuo Suzuki; Mamoru Watanabe; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2020-03-06

2.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Authors:  Parambir S Dulai; Brigid S Boland; Siddharth Singh; Khadija Chaudrey; Jenna L Koliani-Pace; Gursimran Kochhar; Malav P Parikh; Eugenia Shmidt; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Diana Whitehead; Robert Hirten; Adam C Winters; Leah G Katta; Farhad Peerani; Neeraj Narula; Keith Sultan; Arun Swaminath; Matthew Bohm; Dana Lukin; David Hudesman; John T Chang; Jesus Rivera-Nieves; Vipul Jairath; G Y Zou; Brian G Feagan; Bo Shen; Corey A Siegel; Edward V Loftus; Sunanda Kane; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Karen Lasch; Charlie Cao
Journal:  Gastroenterology       Date:  2018-05-30       Impact factor: 22.682

Review 3.  Mechanisms and function of autophagy in intestinal disease.

Authors:  Kara G Lassen; Ramnik J Xavier
Journal:  Autophagy       Date:  2018-01-29       Impact factor: 16.016

4.  Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.

Authors:  Soon Man Yoon; Talin Haritunians; Sultan Chhina; Zhenqiu Liu; Shaohong Yang; Carol Landers; Dalin Li; Byong Duk Ye; David Shih; Eric A Vasiliauskas; Andrew Ippoliti; Shervin Rabizadeh; Stephan R Targan; Gil Y Melmed; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

5.  FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.

Authors:  Elliot S Friedman; Yun Li; Ting-Chin David Shen; Jack Jiang; Lillian Chau; Luciano Adorini; Farah Babakhani; Jeffrey Edwards; David Shapiro; Chunyu Zhao; Rotonya M Carr; Kyle Bittinger; Hongzhe Li; Gary D Wu
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

6.  Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.

Authors:  Kristin E Burke; Hamed Khalili; John J Garber; Talin Haritunians; Dermot P B McGovern; Ramnik J Xavier; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

Review 7.  Interrogating host immunity to predict treatment response in inflammatory bowel disease.

Authors:  Jonathan L Digby-Bell; Raja Atreya; Giovanni Monteleone; Nick Powell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-11-25       Impact factor: 46.802

8.  Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.

Authors:  Nienke Z Borren; Grace Conway; John J Garber; Hamed Khalili; Shrish Budree; Himel Mallick; Vijay Yajnik; Ramnik J Xavier; Ashwin N Ananthakrishnan
Journal:  J Crohns Colitis       Date:  2018-04-27       Impact factor: 9.071

9.  Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease.

Authors:  Tanima De; Honghong Zhang; Cristina Alarcon; Bianca Lec; Juan Avitia; Erin Smithberger; Chuyu Chen; Minnie Horvath; Sara Kwan; Mary Young; Sarbani Adhikari; John Kwon; Jennifer Pacheco; Gail Jarvik; Wei-Qi Wei; Frank Mentch; Hakon Hakonarson; Patrick Sleiman; Adam Gordon; John Harley; Jim Linneman; Scott Hebbring; Loukia Parisiadou; Minoli A Perera
Journal:  Pharmacogenet Genomics       Date:  2022-01-01       Impact factor: 2.089

10.  Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease.

Authors:  Dario Sorrentino; Vu Q Nguyen; Kim Love
Journal:  Dig Dis       Date:  2021-02-25       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.